Celldex Therapeutics (NASDAQ:CLDX) Given New $53.00 Price Target at Barclays

Celldex Therapeutics (NASDAQ:CLDX) had its price objective raised by Barclays from $48.00 to $53.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Cantor Fitzgerald decreased their price target on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. UBS Group boosted their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Morgan Stanley reduced their target price on Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Finally, Guggenheim increased their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.46.

Celldex Therapeutics Trading Up 0.4%

Shares of NASDAQ CLDX opened at $41.71 on Friday. Celldex Therapeutics has a twelve month low of $19.72 and a twelve month high of $42.92. The firm has a 50-day moving average of $35.19 and a two-hundred day moving average of $31.54. The company has a market capitalization of $3.27 billion, a price-to-earnings ratio of -9.59 and a beta of 0.87.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. As a group, research analysts predict that Celldex Therapeutics will post -4.36 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its holdings in shares of Celldex Therapeutics by 39.3% during the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after buying an additional 2,279,605 shares in the last quarter. Vanguard Group Inc. lifted its stake in Celldex Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after acquiring an additional 72,817 shares in the last quarter. Bellevue Group AG boosted its position in Celldex Therapeutics by 7.6% during the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after acquiring an additional 250,100 shares during the period. Commodore Capital LP grew its stake in Celldex Therapeutics by 7.8% during the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after acquiring an additional 250,000 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Celldex Therapeutics by 19.5% in the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock valued at $92,282,000 after purchasing an additional 555,579 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.